Two Sigma Investments LP Boosts Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

Two Sigma Investments LP raised its stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 196.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 313,993 shares of the company's stock after buying an additional 208,021 shares during the quarter. Two Sigma Investments LP owned about 0.68% of 4D Molecular Therapeutics worth $1,749,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Point72 Asia Singapore Pte. Ltd. acquired a new position in 4D Molecular Therapeutics during the fourth quarter worth $50,000. ProShare Advisors LLC grew its stake in shares of 4D Molecular Therapeutics by 30.1% in the fourth quarter. ProShare Advisors LLC now owns 16,369 shares of the company's stock valued at $91,000 after acquiring an additional 3,783 shares in the last quarter. Millennium Management LLC grew its stake in shares of 4D Molecular Therapeutics by 1,607.1% in the fourth quarter. Millennium Management LLC now owns 1,420,723 shares of the company's stock valued at $7,913,000 after acquiring an additional 1,337,497 shares in the last quarter. Corton Capital Inc. acquired a new position in shares of 4D Molecular Therapeutics in the fourth quarter valued at about $182,000. Finally, Cubist Systematic Strategies LLC grew its stake in shares of 4D Molecular Therapeutics by 2,084.5% in the fourth quarter. Cubist Systematic Strategies LLC now owns 448,831 shares of the company's stock valued at $2,500,000 after acquiring an additional 428,285 shares in the last quarter. Institutional investors own 99.27% of the company's stock.

4D Molecular Therapeutics Stock Performance

Shares of FDMT stock traded down $0.04 during trading hours on Wednesday, hitting $3.83. 251,820 shares of the company were exchanged, compared to its average volume of 828,044. The firm has a market cap of $177.42 million, a P/E ratio of -1.34 and a beta of 2.87. 4D Molecular Therapeutics, Inc. has a fifty-two week low of $2.24 and a fifty-two week high of $28.93. The company has a 50 day simple moving average of $3.24 and a two-hundred day simple moving average of $4.72.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.02). As a group, sell-side analysts expect that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on FDMT shares. Barclays reduced their price objective on shares of 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating on the stock in a research note on Friday, May 9th. Royal Bank of Canada dropped their price objective on shares of 4D Molecular Therapeutics from $39.00 to $35.00 and set an "outperform" rating for the company in a report on Monday, March 3rd. HC Wainwright reiterated a "buy" rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a report on Monday, March 3rd. Chardan Capital dropped their price objective on shares of 4D Molecular Therapeutics from $28.00 to $25.00 and set a "buy" rating for the company in a report on Friday, May 9th. Finally, Bank of America dropped their price objective on shares of 4D Molecular Therapeutics from $42.00 to $40.00 and set a "buy" rating for the company in a report on Monday, March 10th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $29.56.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.